Adjuvant Therapy for Pancreas Cancer: Advances and Controversies

Seminars in Oncology

Volumn 34, Issue 4, 2007, Pages 321-326

  Mulcahy, Mary F ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; GEMCITABINE; MITOMYCIN;

ADJUVANT THERAPY; ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CONTINUOUS INFUSION; HUMAN; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; PANCREAS CANCER; PRIORITY JOURNAL; UNITED STATES;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS; COMBINED MODALITY THERAPY; HUMANS; NEOADJUVANT THERAPY; PANCREATIC NEOPLASMS; RADIOTHERAPY, ADJUVANT;

EID: 34547436321     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2007.05.006     Document Type: Article

References (42)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2007. CA Cancer J Clin 57 (2007) 43-66
2. Kelsen D.P., Portenoy R., Thaler H., et al. Pain as a predictor of outcome in patients with operable pancreatic carcinoma. Surgery 122 (1997) 53-59
3. AJCC Cancer Staging Manual. (ed 6) (2002), Springer-Verlag, New York, NY
4. Varadhachary G.R., Tamm E.P., Crane C., et al. Borderline resectable pancreatic cancer. Curr Treat Options Gastroenterol 8 (2005) 377-384
5. Saldinger P.F., Reilly M., Reynolds K., et al. Is CT angiography sufficient for prediction of resectability of periampullary neoplasms?. J Gastrointest Surg 4 (2000) 233-237
6. Valls C., Andia E., Sanchez A., et al. Dual-phase helical CT of pancreatic adenocarcinoma: Assessment of resectability before surgery. AJR 178 (2002) 821-826
7. Sheridan M.B., Ward J., Guthrie J.A., et al. Dynamic contrast-enhanced MR imaging and dual-phase helical CT in the preoperative assessment of suspected pancreatic cancer: A comparative study with receiver operating characteristic analysis. AJR 173 (1999) 583-590
8. Wiersema M.J. Accuracy of endoscopic ultrasound in diagnosing and staging pancreatic carcinoma. Pancreatology 1 (2001) 625-632
9. Raut C.P., Grau A.M., Staerkel G.A., et al. Diagnostic accuracy of endoscopic ultrasound-guided fine-needle aspiration in patients with presumed pancreatic cancer. J Gastrointest Surg 7 (2003) 118-126
10. Nishiyama Y., Yamamoto Y., Yokoe K., et al. Contribution of whole body FDG-PET to the detection of distant metastasis in pancreatic cancer. Ann Nucl Med 19 (2005) 491-497
11. Pietrabissa A., Caramella D., Di Candio G., et al. Laparoscopy and laparoscopic ultrasonography for staging pancreatic cancer: Critical appraisal. World J Surg 23 (1999) 998-1002
12. Fernandez-del Castillo C., Rattner D.W., and Warshaw A.L. Further experience with laparoscopy and peritoneal cytology in the staging of pancreatic cancer. Br J Surg 82 (1995) 1127-1129
13. Borbath I., Van Beers B.E., Lonneux M., et al. Preoperative assessment of pancreatic tumors using magnetic resonance imaging, endoscopic ultrasonography, positron emission tomography and laparoscopy. Pancreatology 5 (2005) 553-561
14. Westerdahl J., Andren-Sandberg A., and Ihse I. Recurrence of exocrine pancreatic cancer-Local or hepatic?. Hepatogastroenterology 40 (1993) 384-387
15. Griffin J.F., Smalley S.R., Jewell W., et al. Patterns of failure after curative resection of pancreatic carcinoma. Cancer 66 (1990) 56-61
16. Kalser M.H., and Ellenberg S.S. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 120 (1985) 899-903
17. Gastrointestinal Tumor Study Group. Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Cancer 59 (1987) 2006-2010
18. Foo M.L., Gunderson L.L., Nagorney D.M., et al. Patterns of failure in grossly resected pancreatic ductal adenocarcinoma treated with adjuvant irradiation +/- 5 fluorouracil. Int J Radiat Oncol Biol Phys 26 (1993) 483-489
19. Yeo C.J., Abrams R.A., Grochow L.B., et al. Pancreaticoduodenectomy for pancreatic adenocarcinoma: Postoperative adjuvant chemoradiation improves survival. A prospective, single-institution experience. Ann Surg 225 (1997) 621-633
20. Demeure M.J., Doffek K.M., Komorowski R.A., et al. Molecular metastases in stage I pancreatic cancer: Improved survival with adjuvant chemoradiation. Surgery 124 (1998) 663-669
21. Mehta V.K., Fisher G.A., Ford J.M., et al. Adjuvant radiotherapy and concomitant 5-fluorouracil by protracted venous infusion for resected pancreatic cancer. Int J Radiat Oncol Biol Phys 48 (2000) 1483-1487
22. Klinkenbijl J.H., Jeekel J., Sahmoud T., et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: Phase III trial of the EORTC Gastrointestinal Tract Cancer Cooperative Group. Ann Surg 230 (1999) 776-782
23. Moertel C.G., Frytak S., Hahn R.G., et al., The Gastrointestinal Tumor Study Group. Therapy of locally unresectable pancreatic carcinoma: A randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil. Cancer 48 (1981) 1705-1710
24. Smalley S.R., Kimler B.F., and Evans R.G. 5-Fluorouracil modulation of radiosensitivity in cultured human carcinoma cells. Int J Radiat Oncol Biol Phys 20 (1991) 207-211
25. O'Connell M.J., Martenson J.A., Wieand H.S., et al. Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. N Engl J Med 331 (1994) 502-507
26. Mehta V.K., Poen J.C., Ford J.M., et al. Protracted venous infusion 5-fluorouracil with concomitant radiotherapy compared with bolus 5-fluorouracil for unresectable pancreatic cancer. Am J Clin Oncol 24 (2001) 155-159
27. Rich T.A., Lokich J.J., and Chaffey J.T. A pilot study of protracted venous infusion of 5-fluorouracil and concomitant radiation therapy. J Clin Oncol 3 (1985) 402-406
28. Poen J.C., Collins H.L., Niederhuber J.E., et al. Chemo-radiotherapy for localized pancreatic cancer: Increased dose intensity and reduced acute toxicity with concomitant radiotherapy and protracted venous infusion 5-fluorouracil. Int J Radiat Oncol Biol Phys 40 (1998) 93-99
29. Shewach D.S., and Lawrence T.S. Radiosensitization of human solid tumor cell lines with gemcitabine. Semin Oncol 23 (1996) 65-71
30. Demols A., Peeters M., Polus M., et al. Adjuvant gemcitabine and concurrent continuous radiation (45 Gy) for resected pancreatic head carcinoma: A multicenter Belgian phase II study. Int J Radiat Oncol Biol Phys 62 (2005) 1351-1356
31. Allen A.M., Zalupski M.M., Robertson J.M., et al. Adjuvant therapy in pancreatic cancer: Phase I trial of radiation dose escalation with concurrent full-dose gemcitabine. Int J Radiat Oncol Biol Phys 59 (2004) 1461-1467
32. Picozzi V.J., Kozarek R.A., and Traverso L.W. Interferon-based adjuvant chemoradiation therapy after pancreaticoduodenectomy for pancreatic adenocarcinoma. Am J Surg 185 (2003) 476-480
33. Neoptolemos J.P., Stocken D.D., Friess H., et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 350 (2004) 1200-1210
34. Choti M.A. Adjuvant therapy for pancreatic cancer-The debate continues. N Engl J Med 350 (2004) 1249-1251
35. Crane C.H., Ben-Josef E., and Small Jr. W. Chemotherapy for pancreatic cancer. N Engl J Med 350 (2004) 2713-2715
36. Regine W.F., Winter K.W., Abrams R., et al. RTOG 9704 a phase III study of adjuvant pre and post chemoradiation (CRT) 5-FU vs. gemcitabine for resected pancreatic adenocarcinoma. J Clin Oncol 24 (2006) 1802
37. Oettle H., Post S., Neuhaus P., et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: A randomized controlled trial. JAMA 297 (2007) 267-277
38. Kim H.J., Czischke K., Brennan M.F., et al. Does neoadjuvant chemoradiation downstage locally advanced pancreatic cancer?. J Gastrointest Surg 6 (2002) 763-769
39. Hoffman J.P., Lipsitz S., Pisansky T., et al. Phase II trial of preoperative radiation therapy and chemotherapy for patients with localized, resectable adenocarcinoma of the pancreas: An Eastern Cooperative Oncology Group study. J Clin Oncol 16 (1998) 317-323
40. Talamonti M.S., Small Jr. W., Mulcahy M.F., et al. A multi-Institutional phase II trial of preoperative full-dose gemcitabine and concurrent radiation for patients with potentially resectable pancreatic carcinoma. Ann Surg Oncol 12 (2005) 1-9
41. Moore M.J., Goldstein D., Hamm J., et al. Erlotinib plus gemcitabine compared to gemcitabine alone in patients with advanced pancreatic cancer. A phase III trial of the National Cancer Institute of Canada Clinical Trials Group [NCIC-CTG]. J Clin Oncol 23 (2005) 1 (suppl 16, abstr)
42. Ramanathan R.K., Lee K.M., McKolanis J., et al. Phase I study of a MUC1 vaccine composed of different doses of MUC1 peptide with SB-AS2 adjuvant in resected and locally advanced pancreatic cancer. Cancer Immunol Immunother 54 (2005) 254-264